Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, announces a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro’s data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicine solutions to cancer and other critical disease areas.

Read the full article: Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine //

Source: https://www.globenewswire.com/news-release/2025/02/26/3033213/0/en/Renovaro-and-BioSymetrics-Announce-Definitive-Merger-Agreement-to-Advance-AI-Driven-Biomarker-Discovery-and-Precision-Medicine.html

Scroll to Top